| [1] |
魏泓.医学动物实验技术[M].北京:人民卫生出版社, 2016.
|
| [2] |
HAMMER H S. Water quality for zebrafish culture[M]. The Zebrafish in Biomedical Research. Academic Press, 2020.
|
| [3] |
JOÃO B, TEIXEIRA D, MICHAEL A, et al.. Toxicology of Essential and Xenobiotic Metals[M]. Boca Raton: CRC Press, 2024.
|
| [4] |
COPPOLA A, LOMBARI P, MAZZELLA E, et al.. Zebrafish as a model of cardiac pathology and toxicity: spotlight on uremic toxins[J/OL]. Int. J. Mol. Sci., 2023, 24(6): 5656[2026-03-11]. .
|
| [5] |
COOPER G, NORTH R, HUNT-SMITH T, et al.. Persistent metabolic changes are induced by 24 h low-dose lead (Pb) exposure in zebrafish embryos[J/OL]. Int. J. Mol. Sci., 2025, 26(3): 1050[2026-03-11]. .
|
| [6] |
MEUSER A V, PITURA A R, MANDEVILLE E G. A high-quality reference genome for the common creek chub, Semotilus atromaculatus [J/OL]. G3, 2024, 14(2): jkad283[2026-03-11]. .
|
| [7] |
DENG Y, QIAN Y, MENG M, et al.. Extensive sequence divergence between the reference genomes of two zebrafish strains, Tuebingen and AB[J]. Mol. Ecol. Resour., 2022, 22(6): 2148-2157.
|
| [8] |
李玉姣,郭健敏,黄远铿,等.斑马鱼在药理毒理研究中的应用进展[J].中南药学,2024,22(10):2725-2728.
|
|
LI Y J, GUO J M, HUANG Y K, et al.. Progress in the application of zebrafish in pharmacological and toxicological research[J]. Cent. South Pharm., 2024, 22(10): 2725-2728.
|
| [9] |
SASSEN W A, KÖSTER R W. A molecular toolbox for genetic manipulation of zebrafish[J]. Adv. Genom. Genet., 2015, 5: 151-163.
|
| [10] |
HUANG M, JIA Z, LIU Y, et al.. A zebrafish immunodeficiency model induced by the combination of Tacrolimus and Everolimus for rapid assessment of immune-enhancing agents[J/OL]. BioRxiv, 2025, 4: 647472[2026-01-12]. .
|
| [11] |
FEHRENBACH A, MITROFANOV A, ALKHNBASHI O S, et al.. SpacerPlacer: ancestral reconstruction of CRISPR arrays reveals the evolutionary dynamics of spacer deletions[J]. Nucleic Acids Res., 2024, 52(18): 10862-10878.
|
| [12] |
SHAMSUDHEEN M S. Beyond the scissors: CRISPR-Cas9's precision in CAR-T cell therapy[J/OL]. J. Biol. Life Sci., 2025, 16(2): 57[2026-03-11]. .
|
| [13] |
张俊有,王棨临,刘倩,等.CRISPR/Cas基因编辑技术在增强子功能分析及鉴定中的研究进展[J].中国生物工程杂志,2022,42(4):24-32.
|
|
ZHANG J Y, WANG Q L, LIU Q, et al.. Research progress of CRISPR/Cas gene editing technology in enhancer function analysis and identification[J]. China Biotechnol., 2022, 42(4): 24-32.
|
| [14] |
ALVARES K V, SILVA J F, DE OLIVEIRA C L B. Shaping agricultural future: a comprehensive review on crispr technology applications in agriculture[J/OL]. Rev. Bras. De Engenharia De Biossistemas, 2024, 18: 1227[2026-03-11]. .
|
| [15] |
贾名扬,王磊,陈俊峰,等.CRISPR/Cas9基因编辑技术在畜禽育种中的研究进展[J].生物技术进展,2024,14(4):529-536.
|
|
JIA M Y, WANG L, CHEN J F, et al.. Research progress of CRISPR/Cas9 gene editing technology in livestock and poultry breeding[J]. Curr. Biotechnol., 2024, 14(4): 529-536.
|
| [16] |
李仪扬,周执政,王淑菲,等.CRISPR/Cas9基因编辑技术在疾病治疗中的应用与展望[J].生物技术进展,2025,15(1):35-42.
|
|
LI Y Y, ZHOU Z Z, WANG S F, et al.. Application and prospect of CRISPR/Cas9 gene editing technology in disease treatment[J]. Curr. Biotechnol., 2025, 15(1): 35-42.
|
| [17] |
KOGA A, SUZUKI M, INAGAKI H, et al.. Transposable element in fish[J/OL]. Nature, 1996, 383(6595): 30[2026-03-11]. .
|
| [18] |
SANDOVAL-VILLEGAS N, NURIEVA W, AMBERGER M, et al.. Contemporary transposon tools: a review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering[J/OL]. Int. J. Mol. Sci., 2021, 22(10): 5084[2026-03-11]. .
|
| [19] |
WANG P C, DENG H, XU R, et al.. Improvement in Tol2 transposon for efficient large-cargo capacity transgene applications in cultured cells and zebrafish (Danio rerio)[J]. Zool. Res., 2024, 45(3): 567-574.
|
| [20] |
DING Y, VAN DER KOLK K J, VAN DER ENT W, et al.. Automated microinjection for zebrafish xenograft models[J/OL]. NPJ Biomed. Innov., 2025, 2: 13[2026-03-11]. .
|
| [21] |
SOMASAGARA R R, HUANG X, XU C, et al.. Targeted therapy of human leukemia xenografts in immunodeficient zebrafish[J/OL]. Sci. Rep., 2021, 11: 5715[2026-03-11]. .
|
| [22] |
黄晞傲.斑马鱼异种移植肿瘤模型在抗肿瘤药物开发具有广阔前景[J/OL].医学与公共健康,2025, 1(6): 2[2026-01-12].
|
|
HUANG X. Zebrafish xenograft tumor models hold broad prospects in antitumor drug development[J/OL]. Med. Public Health, 2025, 1(6): 2[2026-01-12]. .
|
| [23] |
MYERS T D. Investigation of pathological processes in a novel murine model of triosephosphate isomerase deficiency and assessment of potential therapeutics[D]. University of Pittsburgh, 2024.
|
| [24] |
SUN P, LI Y, LIU F, et al.. Generation and analysis of TPI deficiency zebrafish model[J]. Hereditas, 2024, 46(3): 232-241.
|
| [25] |
NIE X, LU Z. Metabolic modulation in dilated cardiomyopathy: from pathophysiology to therapy[J/OL]. Rev. Cardiovasc. Med., 2025, 26(11): 45518[2026-03-11]. .
|
| [26] |
LAMPUGNANI M G, DEJANA E, GIAMPIETRO C. Vascular endothelial (VE)-cadherin, endothelial adherens junctions, and vascular disease[J/OL]. Cold Spring Harb. Perspect. Biol., 2018, 10(10): a029322[2026-03-11]. .
|
| [27] |
LU S, HU M, WANG Z, et al.. Generation and application of the zebrafish heg1 mutant as a cardiovascular disease model[J/OL]. Biomolecules, 2020, 10(11): 1542[2026-03-11]. .
|
| [28] |
GROSS A, ZHOU B, BEWERSDORF L, et al.. Desmoplakin maintains transcellular keratin scaffolding and protects from intestinal injury[J]. Cell. Mol. Gastroenterol. Hepatol., 2022, 13(4): 1181-1200.
|
| [29] |
WANG W, MURRAY B, TICHNELL C, et al.. Clinical characteristics and risk stratification of desmoplakin cardiomyopathy[J]. Europace, 2022, 24(2): 268-277.
|
| [30] |
CELEGHIN R, RISATO G, BEFFAGNA G, et al.. A novel DSP zebrafish model reveals training- and drug-induced modulation of arrhythmogenic cardiomyopathy phenotypes[J/OL]. Cell Death Discov., 2023, 9: 441[2026-03-11]. .
|
| [31] |
MERCATALI L, LA MANNA F, GROENEWOUD A, et al.. Development of a patient-derived xenograft (PDX) of breast cancer bone metastasis in a zebrafish model[J/OL]. Int. J. Mol. Sci., 2016, 17(8): 1375[2026-03-11]. .
|
| [32] |
YIN J, ZHAO G, KALIRAI H, et al.. Zebrafish patient-derived xenograft model as a preclinical platform for uveal melanoma drug discovery[J/OL]. Pharmaceuticals, 2023, 16(4): 598[2026-03-11]. .
|
| [33] |
YENİ Y, NİNİNG N. Homology modeling epitopes of Kirsten rat sarcoma (KRAS) G12D, G12V and G12R as pancreatic ductal adenocarcinoma vaccine candidates[J]. Turk. Comput. Theor. Chem., 2023, 7(1): 62-71.
|
| [34] |
BUDAGYAN K, CANNON A C, CHATOFF A, et al.. KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation[J/OL]. Cell Rep., 2025, 44(4): 115444[2026-03-11]. .
|
| [35] |
NGUYEN A T, EMELYANOV A, KOH C H V, et al.. A high level of liver-specific expression of oncogenic KrasV12 drives robust liver tumorigenesis in transgenic zebrafish[J]. Dis. Models Mech., 2011, 4(6): 801-813.
|
| [36] |
AI X, YE Z, XIAO C, et al.. Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish[J/OL]. Dis. Models Mech., 2022, 15(4): dmm049109[2026-03-11]. .
|
| [37] |
JIN Y, WEI L, JIANG Q, et al.. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model[J/OL]. Sci. Rep., 2018, 8: 15837[2026-03-11]. .
|
| [38] |
MAMMANA A. Skin as a promising biomatrix for the early detection of misfolded proteins by RT-QuIC[D]. Alma Mater Studiorum Università di Bologna, 2023.
|
| [39] |
王晶莹,任彬彬,马素娜,等.α-突触核蛋白在帕金森疾病中诱导线粒体损伤的机制[J].中国组织工程研究,2025,29(17):3668-3674.
|
|
WANG J Y, REN B B, MA S N, et al.. Mechanism of alpha-synuclein in mitochondrial damage induced by Parkinson's disease[J]. Chin. J. Tissue Eng. Res., 2025, 29(17): 3668-3674.
|
| [40] |
ZINI S, MUSCÒ A, LONGHENA F, et al.. A novel stable transgenic zebrafish line expressing mCherry-tagged human alpha-synuclein in the nervous system and exhibiting all the key features of Lewy body disorders at larval stage[J/OL]. Neurobiol. Dis., 2025, 213: 107018[2026-03-11]. .
|
| [41] |
FERREIRA J. A new zebrafish epilepsy model[J/OL]. Lab Anim., 2025, 54(8): 196[2026-03-11]. .
|
| [42] |
BREIJYEH Z, KARAMAN R. Comprehensive review on Alzheimer's disease: causes and treatment[J/OL]. Molecules, 2020, 25(24): 5789[2026-03-11]. .
|
| [43] |
PU Y Z, LIANG L, FU A L, et al.. Generation of Alzheimer's disease transgenic zebrafish expressing human APP mutation under control of zebrafish appb promotor[J]. Curr. Alzheimer Res., 2017, 14(6): 668-679.
|
| [44] |
MEGHADRI S H, MARTINEZ-DELGADO B, OSTERMANN L, et al.. Loss of serpina1 in mice leads to altered gene expression in inflammatory and metabolic pathways[J/OL]. Int. J. Mol. Sci., 2022, 23(18): 10425[2026-03-11]. .
|
| [45] |
DE GRACIA L, NORIEGA L, SÁNCHEZ E, et al.. Protease S and Z inhibitor genotypes in the SERPINA1 gene in patients with COPD in the republic of Panama [J/OL]. Genet. Clin. Genom., 2025: 3(1): 11-17.
|
| [46] |
YIP E, GIOUSOH A, FUNG C, et al.. A transgenic zebrafish model of hepatocyte function in human Z α1-antitrypsin deficiency[J]. Biol. Chem., 2019, 400(12): 1603-1616.
|
| [47] |
ZHANG Q, LI F, GE Q, et al.. YBX1/CD36 positive feedback loop-mediated lipid accumulation drives metabolic dysfunction-associated steatotic liver disease[J]. Int. J. Biol. Sci., 2025, 21(5): 2118-2134.
|
| [48] |
WU S Y, YANG W Y, CHENG C C, et al.. Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling[J/OL]. Clin. Transl. Med., 2020, 10(8): e252[2026-03-11]. .
|
| [49] |
POON K L, WANG X, NG A S, et al.. Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates[J]. Arch. Toxicol., 2017, 91(3): 1187-1197.
|